Clinical efficacy of anti-programmed death ligand 1 antibody HFC-L1/c4G12 in dogs with malignant tumors: an exploratory study.

Takagi S, Tagawa M, Maekawa N, Konnai S, Kagawa Y, Hosoya K, Yamauchi A, Kudo A, Kamo S, Kim S, Kinoshita R, Deguchi T, Owaki R, Tachibana Y, Yokokawa M, Takeuchi H, Nakamura H, Kato Y, Kanazawa S, Abe T, Furuta T, Yamamoto K, Suzuki Y, Okagawa T, Murata S, Ohashi K

Open source

DOI: 10.1292/jvms.25-0303
Published: 2025 Dec 1
Container: The Journal of veterinary medical science
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1292/jvms.25-0303,
  title = {Clinical efficacy of anti-programmed death ligand 1 antibody HFC-L1/c4G12 in dogs with malignant tumors: an exploratory study.},
  author = {Takagi S and Tagawa M and Maekawa N and Konnai S and Kagawa Y and Hosoya K and Yamauchi A and Kudo A and Kamo S and Kim S and Kinoshita R and Deguchi T and Owaki R and Tachibana Y and Yokokawa M and Takeuchi H and Nakamura H and Kato Y and Kanazawa S and Abe T and Furuta T and Yamamoto K and Suzuki Y and Okagawa T and Murata S and Ohashi K},
  year = {2025},
  journal = {The Journal of veterinary medical science},
  doi = {10.1292/jvms.25-0303},
  url = {https://doi.org/10.1292/jvms.25-0303}
}

RIS

TY  - JOUR
TI  - Clinical efficacy of anti-programmed death ligand 1 antibody HFC-L1/c4G12 in dogs with malignant tumors: an exploratory study.
AU  - Takagi S
AU  - Tagawa M
AU  - Maekawa N
AU  - Konnai S
AU  - Kagawa Y
AU  - Hosoya K
AU  - Yamauchi A
AU  - Kudo A
AU  - Kamo S
AU  - Kim S
AU  - Kinoshita R
AU  - Deguchi T
AU  - Owaki R
AU  - Tachibana Y
AU  - Yokokawa M
AU  - Takeuchi H
AU  - Nakamura H
AU  - Kato Y
AU  - Kanazawa S
AU  - Abe T
AU  - Furuta T
AU  - Yamamoto K
AU  - Suzuki Y
AU  - Okagawa T
AU  - Murata S
AU  - Ohashi K
PY  - 2025
JO  - The Journal of veterinary medical science
DO  - 10.1292/jvms.25-0303
UR  - https://doi.org/10.1292/jvms.25-0303
ER  -

APA

S, T., M, T., N, M., S, K., Y, K., K, H., A, Y., A, K., S, K., S, K., R, K., T, D., R, O., Y, T., M, Y., H, T., H, N., Y, K., S, K., T, A., T, F., K, Y., Y, S., T, O., S, M., & K, O. (2025). Clinical efficacy of anti-programmed death ligand 1 antibody HFC-L1/c4G12 in dogs with malignant tumors: an exploratory study.. The Journal of veterinary medical science. https://doi.org/10.1292/jvms.25-0303

Source records

pubmed · retrieved 2026-09-27T08:33:50.507Z